HANCOCK II MITRAL BIOPROSTHETIC HEART VALVE
Report
- Report Number
- 2025587-2019-03045
- Event Type
- Injury
- Date Received
- October 4, 2019
- Date of Event
- November 1, 2006
- Report Date
- October 4, 2019
- Manufacturer
- MEDTRONIC HEART VALVES DIVISION
- Product Code
- LWR
- PMA / PMN Number
- P980043
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- IT
- Reporter Occupation
- PHYSICIAN
Narratives
CITATION: BOTTIO T ET AL. COMMISSURAL DEHISCENCE: A RARE AND PECULIAR CAUSE OF PORCINE VALVE STRUCTURAL DETERIORATION. J THORAC CARDIOVASC SURG. 2006 NOV;132(5):1017-22. DOI: 10.1016/J.JTCVS.2006.06.012. EARLIEST DATE OF PUBLISH USED FOR EVENT DATE (MONTH AND YEAR VALID). NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. WITHOUT THE RETURN OF THE PRODUCT, NO DEFINITIVE CONCLUSION CAN BE MADE REGARDING THE CLINICAL OBSERVATIONS. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
MEDTRONIC RECEIVED INFORMATION VIA LITERATURE REGARDING AN EXAMINATION THE RATE AND MODE OF OCCURRENCE OF COMMISSURAL DEHISCENCE IN FIRST- AND SECOND-GENERATION PORCINE BIOPROSTHETIC VALVE EXPLANTS. ALL DATA WERE COLLECTED FROM A SINGLE CENTER BETWEEN JANUARY 1970 AND JANUARY 2004. THE STUDY ANALYZED 586 EXPLANTED BIOPROSTHESES. PATIENT DEMOGRAPHICS: PREDOMINANTLY FEMALE WITH A MEAN AGE OF 65 YEARS. OF THE EXPLANTED VALVES, 455 WERE MEDTRONIC HANCOCK STANDARD (104 AORTIC POSITION, 338 MITRAL POSITION, 13 TRICUSPID POSITION) AND 31 WERE MEDTRONIC HANCOCK II (6 AORTIC POSITION, 24 MITRAL POSITION, 1 TRICUSPID POSITION). NO SERIAL NUMBERS WERE PROVIDED. AMONG ALL HANCOCK STANDARD AND HANCOCK II PATIENTS, ADVERSE EVENTS INCLUDED: REOPERATION DUE TO STRUCTURAL VALVE DETERIORATION (MOSTLY A RESULT OF DYSTROPHIC CALCIFICATION), VALVE REPLACEMENT DUE TO VALVE INCOMPETENCE CAUSED BY COMMISSURAL DEHISCENCE (OBSERVED WITH HANCOCK STANDARD AND HANCOCK II MITRAL RECIPIENTS), CALCIFICATION/CALCIFIC DEPOSITS, AND VALVE ¿TEARS AND WEARS.¿ FOR ALL HANCOCK STANDARD AND HANCOCK II RECIPIENTS, VALVE EXPLANTATION OCCURRED AT A MEAN TIME OF 10 YEARS POST IMPLANT. BASED ON THE AVAILABLE INFORMATION, MEDTRONIC PRODUCT WAS DIRECTLY ASSOCIATED WITH THE ADVERSE EVENTS. NO ADDITIONAL ADVERSE PATIENT EFFECTS OR PRODUCT PERFORMANCE ISSUES WERE REPORTED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 949954 | HANCOCK II MITRAL BIOPROSTHETIC HEART VALVE | HEART-VALVE, NON-ALLOGRAFT TISSUE | LWR | MEDTRONIC HEART VALVES DIVISION | T510 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 65 YR | Required Intervention |